Natural products such as aromatase inhibitors have been the object of growing attention in recent years
because of their potential to inhibit aromatase with fewer side effects and the possible translation of their current
use as chemotherapeutic agents to future clinical applications in breast cancer chemoprevention. We have
previously investigated CTet, a novel anticancer agent obtained from the broccoli-derived compound indole-3-
carbinol (I3C), that shows great anticancer potential in both in vitro and in vivo studies. Here we evaluated the
potential of CTet as a chemopreventive agent in aromatase expressing MCF-7/AROM-1 breast cancer cells. The
testosterone (TE) aromatization in estradiol (E2) was indirectly evaluated in terms of inhibition of TE-induced cell
proliferation, ERα phosphorylation/activation and Bcl-2 and IGF-1R ERE-regulated protein accumulation. Our results showed that CTet
inhibited TE-driven ERα phosphorylation of both cytosolic and nuclear ERα pools, suggesting an inhibitory effect of TE aromatization in
E2. CTet did not inhibit E2-driven nuclear ERα phosphorylation, but partially inhibited E2-driven cytosolic ERα phosphorylation.
Moreover, CTet inhibited Bcl-2 and IGF-1R accumulation induced by TE but not that which was induced by E2. A cell-free enzymatic
assay showed that CTet did not inhibit aromatase activity directly; however, since CTet treatment induced endoplasmic reticulum stress,
the TE aromatization could be affected because the aromatase enzyme is located within the endoplasmic reticulum. Finally, CTet and
letrozole synergistically inhibited TE-induced cell proliferation. These results showed the potential of the I3C derivative CTet as a
chemopreventive agent that interferes with aromatase activity.